GLP-1 RA use was also associated with reduced risks of major microvascular complications [aHR 0.42, 95% CI 0.35–0.50; RR 0.39, 95% CI 0.33–0.47, a 61% reduction], end-stage kidney disease (aHR 0.08, 95% CI 0.04–0.14), sight-threatening retinopathy (aHR 0.62, 95% CI 0.50–0.76), leg amputation (aHR 0.16, 95% CI 0.05–0.57), and all-cause mortality (aHR 0.38, 95% CI 0.32–0.44) (Table 2). This evidence concerns the gene GLP1R and retinal disorder.